Saurabh Saha, Centessa CEO (BIO19/Endpoints News)
June 2, 2022 10:42 AM EDT
R&D

Centes­sa ax­es lead pro­gram af­ter a pa­tient in kid­ney dis­ease safe­ty study is hos­pi­tal­ized

Max Gelman

Senior Editor

Less than four months af­ter dos­ing the first pa­tients in a piv­otal study for its lead pro­gram, Centes­sa is in­stead re­vers­ing course in a big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

A service from the Financial Times